+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

DNA ploidy in the primary tumor from patients with nonseminomatous testicular germ cell tumors clinical stage I



DNA ploidy in the primary tumor from patients with nonseminomatous testicular germ cell tumors clinical stage I



Cancer 67(7): 1874-1877



The DNA stemline ploidy was assessed in paraffin-embedded, formalin-fixed primary tumor tissue from 68 patients with nonseminomatous germ cell cancer (NSCGT) clinical Stage I (CS I). Forty-three patients had a single aneuploid (greater than 1C) DNA stemline, whereas 24 patients had multiple aneuploid stemlines. In one tumor there was no evidence of an abnormal DNA stemline. Most DNA stemlines had DNA indices around the 3c value. In 13 patients there was a good correlation between the DNA stemline values observed in the primary tumor and in the retroperitoneal lymph node metastases. No correlation was found between the DNA index and the histologic subclassification or the metastatic behavior. The size of the S-phase fraction did not appear to be predictive of subclinical metastases. In CS I patients with NSCGT determination of DNA stemline values does not yield information of predictive or prognostic significance but may contribute to the understanding of the pathogenesis of NSCGT.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 039738067

Download citation: RISBibTeXText

PMID: 1848470

DOI: 10.1002/1097-0142(19910401)67:7<1874::aid-cncr2820670710>3.0.co;2-6


Related references

Importance of a new tumor marker TRA-1-60 in the follow-up of patients with clinical stage I nonseminomatous testicular germ cell tumors. Annals of Surgical Oncology 4(4): 321-327, 1997

Flow cytometric DNA ploidy pattern for predicting metastasis of clinical stage I nonseminomatous germ cell testicular tumors. Urology 41(4): 379-383, 1993

Tumor proliferative activity is predictive of pathological stage in clinical stage A nonseminomatous testicular germ cell tumors. Journal of Urology 155(2): 579-586, 1996

Primary retroperitoneal lymph node dissection for clinical low stage nonseminomatous germ cell testicular tumors. The Journal of Urology 179(4): 175, 2008

Surveillance for patients with clinical stage I nonseminomatous testicular germ cell tumors. World Journal of Urology 33(9): 1351-1357, 2015

The case for observation of patients with clinical stage I nonseminomatous germ cell testicular tumors. Seminars in Urology 11(2): 92-98, 1993

Clinical significance of nuclear DNA ploidy pattern in nonseminomatous germ cell testicular tumors. Urology 43(2): 197-202, 1994

Primary chemotherapy for clinical stage II nonseminomatous germ cell testicular tumors: Selection criteria and long-term results. Mayo Clinic Proceedings 70(9): 821-828, 1995

Risk factors for relapse in patients with clinical stage I testicular nonseminomatous germ cell tumors. Medical Oncology 30(1): 494, 2013

MIB-1 Immunohistochemistry in Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors Predicts Patients at Low Risk for Metastasis. Journal of Urology 160(6): 2291-2292, 1998

MIB-1 immunohistochemistry in clinical stage I nonseminomatous testicular germ cell tumors predicts patients at low risk for metastasis. Cancer. 79(9): 1710-1716, 1997

Serum lactate dehydrogenase isoenzyme 1 and relapse in patients with nonseminomatous testicular germ cell tumors clinical stage I. Acta Oncologica 40(4): 536-540, 2001

Significance of primary tumor size and preorchiectomy serum tumor marker level in predicting pathologic stage at retroperitoneal lymph node dissection in clinical Stage A nonseminomatous germ cell tumors. Urology 69(3): 557-559, 2007

New prognostic parameters to predict pathological stage in clinical stage A nonseminomatous testicular germ cell tumors. Journal of Urology 153(4 Suppl. ): 244A, 1995

Immunohistochemical assessment of tumor proliferation and volume of embryonal carcinoma identify patients with clinical stage A nonseminomatous testicular germ cell tumor at low risk for occult metastasis. Cancer (philadelphia). 75(3): 844-850, 1995